Figure 3. Kaplan–Meier survival curves for JSTS criteria PDTC with high and low EZH2 expression. The estimated 5-year survival rates in the low-expression group were significantly higher compared to the high-expression group for (a) all patients (91.3% vs. 57.1%, p=0.002) and (b) M1 patients (83.3% vs. 40.0%, p=0.008).